Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Excision of a Large Gastrointestinal Stromal Tumour Following 16 Months of Neoadjuvant Therapy with Imatinib (Case Report)

Excision of a Large Gastrointestinal Stromal Tumour Following 16 Months of Neoadjuvant Therapy... Oncol Ther (2019) 7:159–164 https://doi.org/10.1007/s40487-019-00101-4 CASE REPORT Excision of a Large Gastrointestinal Stromal Tumour Following 16 Months of Neoadjuvant Therapy with Imatinib (Case Report) . . . Fousseni Alassani Boyodi Tchangai Aklesso Bagny . . . Ablavi A. Adani-Ife Kossigan A. Amavi Tchin Darre Komla Attipou Received: August 23, 2019 / Published online: November 2, 2019 The Author(s) 2019 shown to be effective in several studies, but the ABSTRACT duration of this treatment is still a subject of debate. Introduction: Although the standard treatment Case report: We report a case of a large GIST of for stromal tumours is surgery, in locally the stomach in a 51-year-old patient with advanced forms, it is often necessary to achieve atypical presentation that was initially unre- tumour downstaging to improve surgical out- sectable. Neoadjuvant treatment with imatinib comes. Neoadjuvant treatment in gastrointesti- for 16 months resulted in a good response, nal stromal tumours (GISTs) with tyrosine allowing secondary surgical excision. kinase inhibitors, including imatinib, has been Conclusion: Imatinib in neoadjuvant therapy should be continued as long as there is a good Enhanced digital features To view enhanced digital features for this article go to https://doi.org/10.6084/ response and tolerance to the medication to http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Excision of a Large Gastrointestinal Stromal Tumour Following 16 Months of Neoadjuvant Therapy with Imatinib (Case Report)

Download PDF
6 pages

Loading next page...
 
/lp/springer-journals/excision-of-a-large-gastrointestinal-stromal-tumour-following-16-K4sk4sPlum
Publisher
Springer Journals
Copyright
Copyright © 2019 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-019-00101-4
Publisher site
See Article on Publisher Site

Abstract

Oncol Ther (2019) 7:159–164 https://doi.org/10.1007/s40487-019-00101-4 CASE REPORT Excision of a Large Gastrointestinal Stromal Tumour Following 16 Months of Neoadjuvant Therapy with Imatinib (Case Report) . . . Fousseni Alassani Boyodi Tchangai Aklesso Bagny . . . Ablavi A. Adani-Ife Kossigan A. Amavi Tchin Darre Komla Attipou Received: August 23, 2019 / Published online: November 2, 2019 The Author(s) 2019 shown to be effective in several studies, but the ABSTRACT duration of this treatment is still a subject of debate. Introduction: Although the standard treatment Case report: We report a case of a large GIST of for stromal tumours is surgery, in locally the stomach in a 51-year-old patient with advanced forms, it is often necessary to achieve atypical presentation that was initially unre- tumour downstaging to improve surgical out- sectable. Neoadjuvant treatment with imatinib comes. Neoadjuvant treatment in gastrointesti- for 16 months resulted in a good response, nal stromal tumours (GISTs) with tyrosine allowing secondary surgical excision. kinase inhibitors, including imatinib, has been Conclusion: Imatinib in neoadjuvant therapy should be continued as long as there is a good Enhanced digital features To view enhanced digital features for this article go to https://doi.org/10.6084/ response and tolerance to the medication to

Journal

Oncology and Therapy – Springer Journals

Published: Nov 2, 2019

References

  • Giant gastrointestinal stromal tumor with predominantly cystic changes: a case report and literature review
    Wang, L; Liu, L; Liu, Z; Tian, Y; Lin, Z
  • Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis
    Miettinen, M; Lasota, J
  • Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
  • Follow-up strategies for patients with gastrointestinal stromal tumour treated with or without adjuvant imatinib after surgery
    Joensuu, H; Martin-Broto, J; Nishida, T; Reichardt, P; Schöffski, P; Maki, RG
  • Asian consensus guidelines for the diagnosis and management of gastrointestinal stromal tumor
    Koo, D-H; Ryu, M-H; Kim, K-M
  • The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines
    Nishida, T; Blay, J-Y; Hirota, S; Kitagawa, Y; Kang, Y-K
  • Effective downsizing of a gastroesophageal GIST using neoadjuvant imatinib mesylate: aA case report
    Asif, S; Gupta, N; Gupta, G; Mehta, A; Singh, S
  • Surgical intervention of a giant gastric gastrointestinal stromal tumor following neoadjuvant therapy with imatinib
    Wang, CY; Ser, KH; Kuan, WS; Lee, WJ
  • Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis treatment and follow up
    Casali, PG; Jost, L; Reichardt, P; Schlemmer, M; Blay, JY
  • Surgical resection of gastrointestinal stromal tumors after treatment with imatinib
    Andtbacka, RH; Ng, CS; Scaife, CL; Cormier, JN; Hunt, KK; Pisters, PW
  • Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665
    Eisenberg, BL; Harris, J; Blanke, CD
  • Neoadjuvant treatment of locally advanced GIST: results of APOLLON, a prospective, open label phase II study in KIT- or PDGFRA-positive tumors
    Hohenberger, P; Langer, C; Wendtner, CM
  • Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib
    Tielen, R; Verhoef, C; Coevorden, F
  • Neoadjuvant Imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG Experience
    Rutkowski, P; Gronchi, A; Hohenberger, P; Bonvalot, S; Schöffski, P; Bauer, S
  • Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor
    Shen, C; Chen, H; Yin, Y; Chen, J; Zhang, B; Chen, Z
  • Neoadjuvant imatinib: longer the better, need to modify risk stratification for adjuvant imatinib
    Ramaswamy, Anant; Jain, Deepak; Sahu, Arvind; Ghosh, Joydeep; Prasad, P; Deodhar, K
  • Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database
    Crosby, JA; Catton, CN; Davis, A
  • Combined surgical and molecular therapy: the gastrointestinal stromal tumor model
    Gold, Jason S; Matteo, Ronald P